Heart Failure POC & LOC Devices Market Overview:
The global heart failure POC & LOC devices market is driven by several factors, such as the increase in cardiovascular diseases and a rise in the geriatric population. Furthermore, the increasing R&D for POC & LOC devices is projected to drive the market in the forecast period. According to WebMD, cardiovascular disease was the leading cause of mortality across the globe in December 2020, with around one-third of all fatalities in 2019, and the death toll is predicted to rise further in the future. In 2019, China had the most heart disease deaths, followed by India, Russia, the US, and Indonesia. Furthermore, according to the United Nations (UN), 727 million people aged 65 years or over were living in 2020, and it is projected that this number would increase to 1.5 billion approximately in 2050.
The industry players focus on new product development and obtain product approvals from the regulatory bodies for more penetration in the global heart failure POC & LOC devices market. For example, in April 2021, Siemens Healthineers (Germany) received the CE mark approval for the AtellicaVTLi Patient-Side Immunoassay Analyzer, a device that provides a point-of-care test to aid in the diagnosis of heart attacks. Furthermore, the key players are involved in new product launches, strategic agreements, and joint ventures to augment their market positions. For instance, in January 2019, Medicure Inc. (Canada) entered an agreement with Sensible Medical Innovations Inc. to market the ReDS point-of-care system to diagnose heart failure.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/10650
Heart failure POC & LOC devices Market Segmentation:
Major test types are metabolomic testing, genomic testing, and proteomic testing. The leading spot belongs to the proteomic testing segment, thanks to the heightened need for biomarker testing with the use of proteomic testing.
The top technologies covered in the report for the heart failure POC & LOC devices industry are array-based systems, microfluidics, and more. The microfluidics category has secured the biggest portion of the market, since this technology facilitates integration as well as miniaturization of majority of the functional protocols utilized in central laboratories into microfluidic biosensors or portable chips.
The top segments, with respect to end user, are specialty centers, homecare, hospitals& clinics, and more.
Heart failure POC & LOC devices Market Regional Analysis:
North America successfully procures the top spot in the worldwide market, thanks to the huge burden of heart conditions like cardiovascular disorder, and more. Large-scale healthcare expenditure combined with the rise in obesity cases add to the market worth as well. Besides, the surging prominence of a poor lifestyle that includes over-consumption of alcohol, smoking, and lack of exercise has foster the vulnerability of people to heart failure. This has created a favorable scenario for the North American market for heart failure POC and LOC devices.
The second position in the heart failure POC and LOC devices market belongs to Europe, and the region can expect more growth in the next couple of years. Surging incidences of cardiovascular diseases combined with the soaring number of heavy smokers amplifies the demand for these devices too. The European industry further benefits from the mushrooming elderly patient base facing a host of heart related issues due to advancing age.
Asia Pacific could expect rapid expansion in subsequent years, thanks to the blossoming patient pool paired with the rising number of technological innovations in healthcare. The fast business growth in the region, especially in India, Singapore, Japan, and China is also the result of the surge in people’s per capita income and the surge in government initiatives to upgrade the healthcare infrastructure.
Heart failure POC & LOC devices Market Players:
The major heart failure POC and LOC devices producers in the market include healrth Danaher (US), bioMérieux S.A (France), Quidel Corporation (US), Siemens Healthineers (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Abaxis, Inc. (US), JantPharmacal Corporation (US), Trinity Biotech (Ireland), Instrumentation Laboratory Company (US), Abbott (US), and more.
Among others are some key companies in the global Heart failure POC & LOC devices that are listed by MRFR for market research.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/heart-failure-poc-and-loc-devices-market-10650
EBR Systems has managed to attain a total funding of AU$110 million in Initial Public Offering on the Australian Securities Exchange (ASX). The company’s WiSE CRT System is the first-ever and the only heart failure-based wireless endocardial left ventricle pacing system. The device offers treatment to those unable to get CRT from a conventional lead-based device or patients that are at high risk associated with an upgrade surgery
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.